The new prefilled syringe has the same composition but removes the need for reconstitution, providing a more convenient option for health care providers who administer vaccines. According to the ...
As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...
On Tuesday, January 7, the FDA announced it would now be requiring GSK and Pfizer’s RSV vaccines to hold warnings of a risk ...
Regulators say, however, the benefits of vaccination with Abrysvo and Arexvy in preventing respiratory syncytial virus ...
Read about vaccine sales, Akums and more in the latest Market Talks covering Health Care.
The FDA has mandated updated safety labeling for two respiratory syncytial virus vaccines, Pfizer's Abrysvo and GlaxoSmithKline's Arexvy, following the identification of an increased risk of ...
The program, which began Dec. 6 in the wake of ongoing H5N1 outbreaks at dairy farms, now includes 28 states covering 65% of the country's milk production. Other public health news is on chronic ...
The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the ...
The change was prompted by postmarketing observational studies that suggest an increased risk of GBS within 42 days of ...
The FDA is adding a warning about Guillain-Barré syndrome to the respiratory syncytial virus vaccines manufactured by GSK and ...
Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.
The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback